Somaxon unveils $86.2M IPO
San Diego-based Somaxon Pharmaceuticals has filed to sell $86.2 million of stock in an upcoming IPO. Much of that money is earmarked for three drug development projects. Somaxon is advancing drug candidates for psychiatry and neurology. Morgan Stanley, JPMorgan, Piper Jaffray and Thomas Weisel Partners are listed as underwriters.
- read this Dow Jones report for more
Comments